That's my view too. Five case studies out of 40 is 12.5%. I would like to see more. Moreover, LP did say that she has been advised against revealing too much and I can understand that too. It would make a bigger impact if all the results were announced in more formal setting such as ASCO which would lend more ligitamacy. But until then, the valuation will linger. But not announcing phase 1 data would provide more ammo to the shorts. I expect that it is most likely scheduled for ACSO. But as Pyrr pointed out, phase 2 results will be the most anticipated.
Also, DCVax-L is still up in the air. There is certainly some comfort for longs due to HE in Germany. The fact that we are building manufacturing in UK is definitely an indication of LP's confidence. But it will not be a contributor to share price until we have some results. I personally hope that they don't decide to stop at interim, even if that is a recommendation of the DMC. Having been a DNDN investor may have something to do that. For those of you who may have followed DNDN in the past years, you may recall that DNDN was sent back to do another phase 3 despite an ADCOM vote of something like 27-3 for safety and efficacy. (Arguments were small size of trial, limited efficacy, cross-overs, etc). If you recall, Howard Scher, who then was the chief clinical investigator for Zytiga, which was still in trials, wrote a letter to then FDA's chairman von Eschenbach against the approval of Provenge. The head of oncology at FDA, Pazdur, was seen passing notes to Maha Hussein who was in the advisory panel who was one of the no votes on efficacy on the ADCOM. Michael Milken (remember him) who set up the Prostate Cancer Foundation and was believed to be a supporter of Zytiga was a friend of von Eschenbach. So I still worry about the larger forces that could impede little NW's progress. I'm more concerned since they are so many big players involved with CI and would love to see NW's delay. I hope the FDA is a cleaner organization now. (Sorry for the rant about DNDN).
By the way, I don;t care a hoot if NWBO has a CFO now or not. Right now it's mostly book-keeping. We do undergo external audits and a formal audit opinion is issued. Auditors do look at related party transactions and whether they are at arms-length. If we were in China or India, then external audits may not carry much weight, but I'm reassured that's this is the US. (Don't beat me on this please. I'm speaking relatively). I live in another country, but I would never buy individual stocks outside the US). We are not generating revenues yet and my opinion is that LP is taking us along on hand-to-mouth, or just-in-time-financing :). That's a another confidence booster for me, because she is expecting share-price to rise in the near future when a secondary will be more productive.
The fact that LP has resisted partnership is also a good sign. Why would one want to partner when one is feeling confident about success? If LP was a scam artist, she would take the money and run. Notwithstanding, I defintely like the idea of combo-partnering with a CI candidate. We need to be in this game while outcomes are still uncertain.
Pyrr has outlined a strategy for us and I fully agree. The only thing I would add is that, never go into a binary event without being partially or fully hedged. This is bio-tech. I'm long and watching closely :)
News 
Market Data 
Discover 
AI
